Comparison between the original biological agents and their biosimilars authorized in portugal

  • At: 2017 FIP Congress in Seoul (South Korea)
  • Type: Poster
  • By: MORGADO, Manuel (University of Beira Interior, Health Science Faculty, Covilhã, Portugal)
  • Co-author(s): Manuel Morgado: Pharmaceutical Services, Hospital Centre of Cova da Beira, Covilhã, Portugal;Health Science Faculty, University of Beira Interior, Covilhã, Portugal
    Ema Paulino: Portuguese Pharmaceutical Society, Lisbon, Portugal
    Andreia Gonçalves: Health Science Faculty, University of Beira Interior, Covilhã, Portugal
    Joana Alves: Health Science Faculty, University of Beira Interior, Covilhã, Portugal
    Marta Fernandes: Health Science Faculty, University of Beira Interior, Covilhã, Portugal
    Miguel Vaz: Health Science Faculty, University of Beira Interior, Covilhã, Portugal
    Sara Fernandes: Health Science Faculty, University of Beira Interior, Covilhã, Portugal
    Sandra Morgado: Pharmaceutical Services, Hospital Centre of Cova da Beira, Covilhã, Portugal
  • Abstract:

    Methods

    Five articles from the PubMed database were retrieved and analyzed, two of which refer to Infliximab (Remicade®) and its biosimilars (Remsima®, Inflectra®) and the remaining three were about Etanercept (Enbrel®) and its biosimilars (Benepali®).

    Results

    Regarding infliximab, the corresponding biosimilars presented similar efficacy,..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login